Coronavirus COVID-19 Daily Update 8th April 2020

Coronavirus COVID-19 Daily Update 8th April 2020

This update will be published daily at 12pm GMT and aims to provide clinicians and the public with an overview of the latest data, guidelines, key publications and policy around COVID-19, with links to essential resources and information.

If you are a healthcare professional, please join the discussion on these latest COVID-19 cases on MedShr:

Please post any COVID-19 cases, images or learning points from your clinical practice on MedShr - share key knowledge and experience with a global network of doctors to help improve patient care. Include #COVID19 in your case title.

Please email if you have any data, publications or information you would like to share.

Global Impact of COVID-19 to Date

As of 8th April 09:00 (GMT)

COVID-19 Cumulative Global Cases

As of 8th April 09:00 (GMT)

COVID-19 Global Active Cases Map

As of 8th April 09:00 GMT

Total UK COVID-19 Cases

As of 7th April

NB: Public Health England has now moved to a different reporting time for UK COVID-19 fatalities, as family consent is now needed to release mortality statistics. Hence the reported figures may not actually be the deaths that have taken place over the past 24 hours, meaning caution needs to be exercised when comparing figures from one day to the next.

COVID-19 Cumulative UK Cases

As of 7th April

COVID-19 Daily UK Cases

As of 7th April

Coronavirus Infection trajectories

As of 8th April 2020

COVID-19 Key Data

Source: J P Morgan

Source: J P Morgan

Excerpt from J P Morgan: Vaccine and anti-viral update; the Chloroquine controversy; Convalescent plasma (Last update 4th April 2020)

Critique of Study by Gautret el al, March 2020: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

  • non-randomized trial with only 36 patients, and had no discussion of outcomes

  • excluded 6 recipients that were not discussed, some of whom of required ventilation and/or died

  • started out with higher viral loads in the control group than in the infected patients, which could explain why the control group showed higher infected rates at the conclusion of the study

  • imputed more than 1/3 of the control group virus tests rather than measuring them

  • sourced its treatment group (unlike the control group) from a single medical center

Source: J P Morgan

Latest Developments



Middle East


United Kingdom


Latest COVID-19 Publications

Some key recent publications to be aware of:

Covid-19: Why Germany’s case fatality rate seems so low

Published 7th April 2020

Germany's low covid-19 fatality rate can be attributed partly to the nation’s early and high level of testing among a wide sample of the German population. While other countries were conducting a limited number of tests of older patients with severe cases of the virus, Germany was conducting many more tests that included milder cases in younger people.

Diagnostic Value and Dynamic Variance of Serum Antibody in Coronavirus Disease 2019

Published 3rd April 2020 (online ahead of print)

International Journal of Infectious Diseases

Investigation on the diagnostic value of serological test and dynamic variance of serum antibody in COVID-19. Concluded that a viral serological test is an effective diagnostic means for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than that of IgM in COVID-19.

Caution and clarity required in the use of chloroquine for COVID-19

Published 2nd April 2020

The Lancet Rheumatology

Caution for use of chloroquine in the clinical setting, although shown to inhibit severe acute respiratory syndrome coronavirus 2 in vitro, benefit of clinical use is still under evaluation. Also care should be taken to review dosing regimens as it can accumulate in the body and reach a lethal dose.

Daily Update by Samantha Goh, MedShr Open Editorial Team, Medical Education Teaching Fellow

Loading Author...


Sign in or Register to comment